Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Vallon Pharmaceuticals stock | $5.1

Learn how to easily invest in Vallon Pharmaceuticals stock.

Vallon Pharmaceuticals Inc
- $0.28 ( - 5.20%)

Vallon Pharmaceuticals completed its $18 million IPO, selling 2.25 million shares at $8 each. Shares of VLON are available for limit orders on Robinhood.

How to buy shares in Vallon Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VLON – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Vallon Pharmaceuticals stock price (NASDAQ: VLON)

Use our graph to track the performance of VLON stocks over time.

Vallon Pharmaceuticals shares at a glance

Information last updated 2021-10-17.
Latest market close$5.10
52-week range$3.61 - $10.36
50-day moving average $7.23
200-day moving average $5.22
Wall St. target price$12.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.39

Buy Vallon Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vallon Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vallon Pharmaceuticals price performance over time

Historical closes compared with the close of $5.1 from 2021-10-22

1 week (2021-10-15) -24.22%
1 month (2021-09-24) -32.36%
3 months (2021-07-23) 7.14%
6 months (2021-04-23) 13.59%
1 year (2020-10-20) N/A
2 years (2019-10-20) N/A
3 years (2018-10-20) N/A
5 years (2016-10-20) N/A

Vallon Pharmaceuticals financials

Gross profit TTM $100,000
Return on assets TTM -65.73%
Return on equity TTM -137.94%
Profit margin 0%
Book value $1.45
Market capitalisation $45.9 million

TTM: trailing 12 months

Shorting Vallon Pharmaceuticals shares

There are currently 77,960 Vallon Pharmaceuticals shares held short by investors – that's known as Vallon Pharmaceuticals's "short interest". This figure is 21.7% down from 99,556 last month.

There are a few different ways that this level of interest in shorting Vallon Pharmaceuticals shares can be evaluated.

Vallon Pharmaceuticals's "short interest ratio" (SIR)

Vallon Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Vallon Pharmaceuticals shares currently shorted divided by the average quantity of Vallon Pharmaceuticals shares traded daily (recently around 389800). Vallon Pharmaceuticals's SIR currently stands at 0.2. In other words for every 100,000 Vallon Pharmaceuticals shares traded daily on the market, roughly 200 shares are currently held short.

To gain some more context, you can compare Vallon Pharmaceuticals's short interest ratio against those of similar companies.

However Vallon Pharmaceuticals's short interest can also be evaluated against the total number of Vallon Pharmaceuticals shares, or, against the total number of tradable Vallon Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vallon Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Vallon Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0244% of the tradable shares (for every 100,000 tradable Vallon Pharmaceuticals shares, roughly 24 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vallon Pharmaceuticals.

Find out more about how you can short Vallon Pharmaceuticals stock.

Vallon Pharmaceuticals share dividends

We're not expecting Vallon Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

Vallon Pharmaceuticals overview

Vallon Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania. .

Frequently asked questions

What percentage of Vallon Pharmaceuticals is owned by insiders or institutions?
Currently 52.813% of Vallon Pharmaceuticals shares are held by insiders and 8.519% by institutions.
How many people work for Vallon Pharmaceuticals?
Latest data suggests 2 work at Vallon Pharmaceuticals.
When does the fiscal year end for Vallon Pharmaceuticals?
Vallon Pharmaceuticals's fiscal year ends in December.
Where is Vallon Pharmaceuticals based?
Vallon Pharmaceuticals's address is: Two Logan Square, Philadelphia, PA, United States, 19103
What is Vallon Pharmaceuticals's ISIN number?
Vallon Pharmaceuticals's international securities identification number is: US92023M1018

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site